

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Contents lists available at ScienceDirect

American Journal of Otolaryngology–Head and Neck Medicine and Surgery

journal homepage: www.elsevier.com/locate/amjoto





The study of recovery rates of COVID-19 olfactory and gustatory dysfunctions requires psychophysical evaluations

ARTICLE INFO

Keywords
COVID-19
Coronavirus
SARS-CoV-2
Anosmia
Hyposmia
Olfactory
Smell
Taste
Psychophysical

Dear Editor,

We read the paper of Biadsee et al. entitled "Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients" [1]. Authors attempted to determine the 8-month recovery rates of olfactory (OD) and gustatory (GD) dysfunctions in coronavirus disease 2019 (COVID-19) patients through a phone-based 7-item telephone questionnaire. At 8-month post-infection, authors observed that 61.5% and 52% of patients self-reported full recovery of smell and taste senses. They concluded that 'complete recovery of smell and taste functions occurred in 52% and 61.5%, respectively'. We acknowledge the authors for this study. However, many methodological points may limit the establishment of reliable conclusions.

First, it is difficult to state that patients had OD and GD because authors based their evaluations on patient-reported outcome questionnaire. Indeed, OD and GD are usually confirmed with the realization of psychophysical olfactory and gustatory evaluations, which are semiobjective (or semi-subjective) testing defining the presence of 'true' smell and taste dysfunctions [2,3]. The use of psychophysical evaluations makes particularly sense in COVID-19 patients because there would exist a mismatch between the prevalence of self-reported OD and the prevalence of psychophysical-based OD (anosmia and hyposmia) [4]. In the study of Biadsee et al., we did not find the definition of 'normal smell sense' in the questionnaire. It is important to specify the definition of normal smell sense because many COVID-19 patients who recovered smell sense may have parosmia, which is a smell disorder [5]. This finding was supported by Hopkins et al., who observed that 43.1% of COVID-19 patients self-reported completed smell recovery at 6 months, but 20.3% of these patients reported persisting smell disorder consisting of parosmia [5].

Second, to assess the taste recovery, the authors used the following question: "Rate your sense of taste to date, on a scale from 0 to 10" [1]. They did not define taste dysfunction that is commonly defined as impairment of salty, sweet, bitter, and sour perception [6]. The use of a

consistent and validated definition of taste/gustatory dysfunction is important because there is confusion in the population about taste and aroma definitions [7]. In other words, many patients think they have taste dysfunction but, after testing, they only have OD and related aroma disorder. The risk of confusion may be reduced further by gustatory psychophysical or objective evaluations that are reliable methods to really evaluate the recovery rate of taste sense. The evaluation of GD with patient-reported outcome questionnaire and without psychophysical gustatory evaluations may perpetuate the confusion.

The last point that needs additional information is the patient management of OD and GD. The authors did not specify if patients received nasal or general treatment (e.g., nasal or oral corticosteroids) or were instructed to respect olfactory or gustatory training during the follow-up period. To date, there are controversial data about the usefulness of olfactory training, nasal or oral corticosteroids [8,9]. Authors that will investigate the recovery of post-COVID-19 smell, taste, and aroma senses have to consider the use of psychophysical olfactory and gustatory evaluations and the types of patient management, including medication or olfactory training advice.

Acknowledgments

None.

References

- Biadsee A, Dagan O, Ormianer Z, Kassem F, Masarwa S, Biadsee A. Eight-month follow-up of olfactory and gustatory dysfunctions in recovered COVID-19 patients. Am J Otolaryngol 2021.
- [2] Schuster B, Iannilli E, Gudziol V, Landis BN. Gustatory testing for clinicians. B-ENT 2009;5(Suppl. 13):109–13.
- [3] Rumeau C, Nguyen DT, Jankowski R. How to assess olfactory performance with the Sniffin' sticks test. Eur Ann Otorhinolaryngol Head Neck Dis Jun 2016;133(3): 203–6. https://doi.org/10.1016/j.anorl.2015.08.004.
- [4] Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Hans S, Calvo-Henriquez C, Martiny D, Journe F, Sowerby L, Saussez S. Objective olfactory evaluation of self-

- reported loss of smell in a case series of 86 COVID-19 patients. Head Neck 2020;42 (7):1583–90. https://doi.org/10.1002/hed.26279.
- [5] Hopkins C, Surda P, Vaira LA, Lechien JR, Safarian M, Saussez S, Kumar N. Six month follow-up of self-reported loss of smell during the COVID-19pandemic. Rhinology 2021;59(1):26–31. https://doi.org/10.4193/Rhin20.544.
- [6] Bhattacharyya N, Kepnes LJ. Contemporary assessment of the prevalence of smell and taste problems in adults. Laryngoscope 2015;125:1102–6. https://doi.org/ 10.1002/lary.24999.
- [7] Stevenson RJ, Oaten MJ, Mahmut MK. The role of taste and oral somatosensation in olfactory localization. Q J Exp Psychol (Hove) 2011 Feb;64(2):224–40. https://doi. org/10.1080/17470218.2010.491922.
- [8] Lechien JR, Hoch CC, Vaira LA, Saussez S. The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated. Am J Otolaryngol 2021: 103008. https://doi.org/10.1016/ji.amjoto.2021.103008.
- [9] Singh CV, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol Jan 16 2021;42(3):102892. https://doi.org/10.1016/j.amjoto.2020.102892.

Jerome R. Lechien a,b,c,d,* , Sven Saussez a,b,c , Antonino Maniaci a,e , Luigi A. Vaira a,f,g

^a COVID-19 Task Force of the Young-Otolaryngologists of the International Federations of Oto-rhino-laryngological Societies (YO-IFOS), Paris, France
 ^b Department of Human Anatomy and Experimental Oncology, Faculty of Medicine, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium

- ^c Department of Otorhinolaryngology and Head and Neck Surgery, CHU de Bruxelles, CHU Saint-Pierre, School of Medicine, Université Libre de Bruxelles, Brussels, Belgium
- ^d Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentinen-Yvelines (Paris Saclay University), Paris, France
- ^e Department of Medical and Surgical Sciences and Advanced Technologies G.F. Ingrassia, ENT Section, University of Catania, Catania, Italy
- ^f Maxillofacial Surgery Operative Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Italy
 - g Biomedical Science PhD School, Biomedical Science Department, University of Sassari, Italy
 - * Corresponding author at: Department of Otorhinolaryngology and Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.

E-mail address: Jerome.Lechien@umons.ac.be (J.R. Lechien).